Abciximab is an antiplatelet agent used to prevent blood clots during percutaneous coronary intervention (PCI) and in patients with unstable angina. It works by blocking glycoprotein IIb/IIIa receptors on platelets, preventing aggregation and thrombus formation. Abciximab is effective in reducing cardiovascular events. In summary, Abciximab is vital for managing acute coronary syndromes.
Abciximab binds to glycoprotein IIb/IIIa receptors on platelets, inhibiting their aggregation and preventing thrombus formation.
No published brands for this salt yet.